Oncology Central

Vistusertib with paclitaxel shows promise for ovarian and lung cancer in early trial

0
In this study, researchers from the Institute of Cancer Research and The Royal Marsden (both London, UK), along with teams at nine other centres across the UK, tested a combination of vistusertib with paclitaxel chemotherapy on 25 women with high-grade, serous ovarian cancer and 40 patients with squamous non-small cell lung cancer.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.